In sum, these data demonstrate that reduced hepatic PLIN2 does not protect against the development of HFD-induced weight and fat mass gain or obesity-associated alterations in insulin–glucose homeostasis early in the progression of NAFLD. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.